DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics - Global Markets by Assay & Cause with Executive and Consultant Guides and COVID-19 Related Sepsis Market Analysis and Forecasts 2020-2025" report has been added to ResearchAndMarkets.com's offering.
Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID-19 Pandemic has increased the sepsis death toll.
The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life-saving diagnostics can command a premium in the market, especially deaths related to COVID-19 infections. Understand the different drivers of this huge global diagnostic market and where the opportunity lies.
The report forecasts the market size out to 2025. Growth is coming from the basic factors but the COVID-19 Pandemic has changed the market landscape now and for the foreseeable future. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnostic and the Genomics Revolution are merging to create new diagnostic opportunities.
Companies Mentioned
- Abbott Diagnostics
- Abionic
- Accel Diagnostics
- Accelerate Diagnostics
- Axis-Shield Diagnostics Ltd
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biocartis
- bioMerieux Diagnostics
- Bruker
- Cube Dx
- Curetis N.V. / Curetis GmbH
- Cytovale
- EKF Diagnostics Holdings
- GeneFluidics
- GenMark Dx
- Grifols
- Immunexpress
- Inflammatix
- Linear Diagnostics
- Luminex Corp
- Mbio Diagnostics
- Mobidiag
- Nanomix
- Qiagen Gmbh
- Response Biomedical
- Roche Molecular Diagnostics
- SeLux Diagnostics
- Septec
- Siemens Healthineers
- Sphingotec
- T2 Biosystems
- Thermo Fisher Scientific Inc
Key Topics Covered:
1. Introduction and Market Definition
2. Sepsis - Current Science
3. Industry Overview
4. Market Trends
4.1 Factors Driving Growth
4.1.1 Increasing Prevalence
4.1.2 Antimicrobial Resistance
4.1.3 Increasing Diagnosis
4.1.4 Multiplex Diagnostics Impacts
4.1.5 The Aging World
4.1.6 COVID-19 Market Impact
4.2 Factors Limiting Growth
4.2.1 The Cost Curve Shrinks the Market
4.2.2 The Diagnostics Dilemma
4.2.3 Adoption Lag and Cost Control
4.3 Diagnostic Technology Development
4.3.1 The Multiplex Opportunity
4.3.2 Shifting Role of Physicians in Diagnosis
4.3.3 Diagnostics Moves Out of the Lab
4.3.4 Biomarkers and Algorithms
4.3.5 Rapid Testing Changing Medical Practice
4.3.6 Genome Role and Big Data
4.3.6 The Next Five Years
5. Sepsis Diagnostics - Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
- SpeeDx Developing Respiratory Virus Host-Response Test
- Scanogen Developing Blood Infection Test with Sepsis Application
- Inflammatix Moving Into COVID Test Market and Developing New Sepsis Dx
- Immunexpress, Biocartis to Roll Out Sepsis Test
- Sepset Biosciences Using COVID-19 Patient Samples to Validate Sepsis Test
- Immunexpress to Develop Sepsis Test for Coronavirus Patient Triage
- DNAe Developing POC Sequencing Platform for Coronavirus, Sepsis
- NGS technique offers quick, accurate diagnosis of sepsis
- Portable device diagnoses sepsis faster
- Ontera and QuantuMDx Collaborate to Advance Sepsis Diagnosis
- Blood Test Accurately Predicts Sepsis Severity
- Sepsis diagnostics: HHS to advance development of Cytovale rapid test
- Mologic Developing Sepsis Test Using Multimarker
- Abionic: Study Demonstrates Diagnosis of Sepsis in 5 Minutes
- T2 Biosystems Introduces New Data and Updates for Rapid Diagnostic Technology
- Sepsis found to fit into 4 subtypes
- GenMark Diagnostics Receives FDA Clearance for Blood Panel
- Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
- New Test Could Diagnose Sepsis Faster
- Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
- Curetis' Unyvero Application Cartridges Receive Regulatory Approvals
- Luminex to Pay $75M for MilliporeSigma's Flow Cytometry Research Portfolio
- Experimental 2.5-minute Sepsis Test Discovered
- sphingotec raises ?20 million
- SeLux Diagnostics Announces Sepsi U.S. HHS/BARDA Research Funding
- Roche PCT assay cleared as tool in fight against Sepsis
- GeneFluidics selected as finalist for AMR Challenge
- BioDirection, Inc. Announces System to Diagnose and Monitor Sepsis
- sphingotec Adding Advanced POC Testing Platform
- Rapid Detection Using DNAe's LiDia Bloodstream Infection Technology
- Septec Team Working on 15 Minute Sepsis Diagnosis
- Abionic Announces Rapid Sepsis PoC Diagnostic
6. Profiles of Key Companies
7. Sepsis Diagnostic Markets
7.1 Sepsis Diagnostics - Global Market Overview by Country
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
8. Global Sepsis Diagnostics Markets - By Assay Type
8.1 Global Market by Diagnostic Type - Overview
8.2 Sepsis Diagnostic - Microbiology
8.3 Sepsis Diagnostic - Syndromic PoC Panel
8.4 Sepsis Diagnostic - Other Infectious Disease
8.5 Sepsis Diagnostic - Biomarker Molecular Diagnostic
8.6 Sepsis Diagnostic - Biomarker Other
9. Global Sepsis Diagnostics Markets - By Cause
9.1 Global Market by Cause - Overview
9.2 Sepsis Diagnostic - GastroIntestinal
9.3 Sepsis Diagnostic - Respiratory COVID-19
9.4 Sepsis Diagnostic - Respiratory Other
9.5 Sepsis Diagnostic - Newborn
9.6 Sepsis Diagnostic - Other Cause
For more information about this report visit https://www.researchandmarkets.com/r/rtiomw
